In This Section

Clinical Paths for Soluble Epoxide Hydrolase Inhibitors

Saturday April 21, 2018

1:30 pm - 4:00 pm Eastern Time (ET)

Room 17A


Chair :

Bruce Hammock
Eicosis and University of California Davis

John Imig
Medical College of Wisconsin

Soluble epoxide hydrolase (sEH) is an enzyme that contributes to metabolism of biologically active lipids including arachidonic acid epoxides (EETs). Soluble epoxide hydrolase inhibitors (sEHIs) were developed as a means to increase epoxides and sEHIs were found to reduce blood pressure, improve insulin sensitivity, and decrease inflammation. Further sEHI development led to clinical trials for hypertension and diabetes. More recently, there has been significant expansion of the potential clinical paths for sEHIs. This symposium will highlight possible clinical paths for sEHIs: 1) Chronic obstructive pulmonary disease (COPD), 2) Chronic kidney disease (CKD), 3) Neuropathic pain, Depression, and other CNS disorders.


John Imig - Medical College of Wisconsin

Soluble Epoxide Hydrolase Inhibitors as Treatments for Renal Fibrosis and Chronic Kidney Disease

Kenji Hashimoto - Chiba University

Soluble Epoxide Hydrolase Inhibitors to Treat Depression and other CNS Related Disorders

Karen Wagner - University of California, Davis

Anti-Nociceptive Mechanisms of Action for Soluble Epoxide Hydrolase Inhibitors

William Schmidt - EicOsis

Clinical Path for Soluble Epoxide Hydrolase Inhibitors to Treat Neuropathic Pain

Dipak Panigraphy - Harvard University, Beth Israel Deaconess Medical Center

Soluble Epoxide Hydrolase and Lipid Mediators in Sepsis and Inflammation

Panel Discussion

Thank you to our Annual Meeting partners:

University of Florida
Wake Forest University
Washington State University College of Pharmacy and Pharmaceutical Sciences
University of Wisconsin Molecular and Cellular Pharmacology Training Program
UT Health San Antonio
University of Minnesota

Emory University Pharmacology

PR & P
University of Michigan Medical School Pharmacology